MX2022013658A - Inhibidores de la aldosa reductasa para tratar la deficiencia de sorbitol deshidrogenasa. - Google Patents

Inhibidores de la aldosa reductasa para tratar la deficiencia de sorbitol deshidrogenasa.

Info

Publication number
MX2022013658A
MX2022013658A MX2022013658A MX2022013658A MX2022013658A MX 2022013658 A MX2022013658 A MX 2022013658A MX 2022013658 A MX2022013658 A MX 2022013658A MX 2022013658 A MX2022013658 A MX 2022013658A MX 2022013658 A MX2022013658 A MX 2022013658A
Authority
MX
Mexico
Prior art keywords
reductase inhibitors
aldose reductase
treating
dehydrogenase deficiency
sorbitol dehydrogenase
Prior art date
Application number
MX2022013658A
Other languages
English (en)
Spanish (es)
Inventor
Shoshana Shendelman
Original Assignee
Applied Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Applied Therapeutics Inc filed Critical Applied Therapeutics Inc
Publication of MX2022013658A publication Critical patent/MX2022013658A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
MX2022013658A 2020-05-01 2021-04-27 Inhibidores de la aldosa reductasa para tratar la deficiencia de sorbitol deshidrogenasa. MX2022013658A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063019186P 2020-05-01 2020-05-01
US202063019738P 2020-05-04 2020-05-04
PCT/US2021/029286 WO2021222165A1 (en) 2020-05-01 2021-04-27 Aldose reductase inhibitors for treating sorbitol dehydrogenase deficiency

Publications (1)

Publication Number Publication Date
MX2022013658A true MX2022013658A (es) 2023-03-01

Family

ID=75954272

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022013658A MX2022013658A (es) 2020-05-01 2021-04-27 Inhibidores de la aldosa reductasa para tratar la deficiencia de sorbitol deshidrogenasa.

Country Status (11)

Country Link
US (2) US20230121312A1 (enExample)
EP (1) EP4135674A1 (enExample)
JP (2) JP7788399B2 (enExample)
KR (1) KR20230005944A (enExample)
CN (1) CN115996725A (enExample)
AU (1) AU2021264454A1 (enExample)
BR (1) BR112022021845A2 (enExample)
CA (1) CA3176768A1 (enExample)
IL (1) IL297779A (enExample)
MX (1) MX2022013658A (enExample)
WO (1) WO2021222165A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL272246B2 (en) 2017-07-28 2026-01-01 Applied Therapeutics Inc History of 2-(4-oxo/thioketone/azo-3-((substituted)benzo[d]thiazol-2-yl)methyl)- 3,4-dihydrothieno[3,4-d]pyridazin-1-yl)acetic acid for use as an aldose reductase inhibitor for the treatment of galactosemia or prevention of galactosemia-related complications
CN113840825A (zh) 2019-04-01 2021-12-24 应用治疗公司 醛糖还原酶抑制剂
MX2021013511A (es) 2019-05-07 2022-02-23 Univ Miami Tratamiento y deteccion de neuropatias heredadas y trastornos asociados.
GB202400033D0 (en) 2024-01-02 2024-02-14 Nicolnson Tamara Therapy i
WO2025219948A1 (en) * 2024-04-17 2025-10-23 Assia Chemical Industries Ltd. Crystalline forms of govorestat

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4939140A (en) 1985-11-07 1990-07-03 Pfizer Inc. Heterocyclic oxophthalazinyl acetic acids
JPH0495025A (ja) 1990-08-08 1992-03-27 Asahi Chem Ind Co Ltd アルドースリダクターゼ阻害剤
US5464961A (en) 1993-09-10 1995-11-07 Olin Corporation Arcjet anode
US5624949A (en) 1993-12-07 1997-04-29 Eli Lilly And Company Protein kinase C inhibitors
CN1200106A (zh) 1995-08-28 1998-11-25 美国家用产品公司 苯氧基乙酸类化合物用作醛糖还原酶抑制剂和抗高血糖药
PL179170B1 (pl) 1995-09-15 2000-07-31 Inst Lekow Nowe zwiazki,pochodne genisteiny PL PL PL PL
ES2122764T3 (es) 1995-11-20 1998-12-16 Lilly Co Eli Inhibidor de la proteina quinasa c.
AU6473898A (en) * 1997-03-21 1998-10-20 Regents Of The University Of California, The Methods for modulating neurotrophic factor-associated activity using aldose reductase inhibitors
GB9714274D0 (en) * 1997-07-08 1997-09-10 Zeneca Ltd Pharmaceutical composition
EP0982306A3 (en) 1998-08-21 2000-07-05 Pfizer Products Inc. Polymorph of zopolrestat monohydrate
US6570013B2 (en) 2000-02-16 2003-05-27 Pfizer Inc Salts of zopolrestat
WO2003105864A1 (en) 2002-06-13 2003-12-24 Board Of Regents, The University Of Texas System Methods and compositions involving aldose reductase inhibitors
EP2065038A1 (en) * 2007-11-30 2009-06-03 Pharnext New therapeutic approaches for treating Charcot-Marie-Tooth disease
HUE031506T2 (en) 2010-07-16 2017-07-28 Univ Columbia Aldose reductase inhibitors and their use
US8916563B2 (en) 2010-07-16 2014-12-23 The Trustees Of Columbia University In The City Of New York Aldose reductase inhibitors and uses thereof
JP6500992B2 (ja) 2015-09-01 2019-04-17 株式会社村田製作所 コイル内蔵部品
ES2966094T3 (es) 2016-06-21 2024-04-18 Univ Columbia Compuestos 4-oxo-3,4-dihidrotieno[3,4-d]piridazina como inhibidores de la aldosa reductasa y métodos de uso de los mismos
IL272246B2 (en) 2017-07-28 2026-01-01 Applied Therapeutics Inc History of 2-(4-oxo/thioketone/azo-3-((substituted)benzo[d]thiazol-2-yl)methyl)- 3,4-dihydrothieno[3,4-d]pyridazin-1-yl)acetic acid for use as an aldose reductase inhibitor for the treatment of galactosemia or prevention of galactosemia-related complications

Also Published As

Publication number Publication date
US20230121312A1 (en) 2023-04-20
JP2023524504A (ja) 2023-06-12
CN115996725A (zh) 2023-04-21
BR112022021845A2 (pt) 2022-12-20
AU2021264454A1 (en) 2022-12-08
WO2021222165A1 (en) 2021-11-04
CA3176768A1 (en) 2021-11-04
US20240238288A1 (en) 2024-07-18
JP7788399B2 (ja) 2025-12-18
EP4135674A1 (en) 2023-02-22
IL297779A (en) 2022-12-01
KR20230005944A (ko) 2023-01-10
JP2026012262A (ja) 2026-01-23

Similar Documents

Publication Publication Date Title
BR112022021845A2 (pt) Inibidores de aldose redutase para tratar deficiência em sorbitol desidrogenase
EP4234587A3 (en) Thermally inhibited starch and process for making
ZA201802331B (en) Stable inoculant compositions and methods for producing same
SA520420007B1 (ar) هوموسرين ديهيدروجيناز معدل وطريقة لإنتاج هوموسرين أو حمض أميني من النوع l مشتق من هوموسرين باستخدام تلك الطريقة
MY187588A (en) Compositions and methods for rapid and dynamic flux control using synthetic metabolic valves
MX2019002069A (es) Metodo para la fabricacion de partes de acero revestidas, endurecidas por presion y laminas de acero pre-revestidas que pueden ser utilizadas para la fabricacion de dichas partes.
PH12019502892A1 (en) Mitoketoscins: mitochondrial-based therapeutics targeting ketone metabolism in cancer cells
EP4446338A3 (en) Cells and method of cell culture
MX2022001491A (es) Factor de transcripcion nterf221 y metodos de uso del mismo.
PH12019502616A1 (en) Approval workflow entrusting and re-entrusting methods
AU2018274709A1 (en) Methods for increasing grain productivity
MY182946A (en) Production of organic acids by fermentation at low ph
ZA202307853B (en) Novel citrate synthase variant and method for producing o-acetyl-l-homoserine or l-methionine using same
MX2019000826A (es) Metodo para proporcionar un recubrimiento de zn-al-mg, y ese recubrimiento.
MY187786A (en) N-acetyl homoserine
PH12019501779A1 (en) Method and device for producing biogas
PH12020550476A1 (en) Mitoflavoscins: targeting flavin-containing enzymes eliminates cancer stem cells (cscs) by inhibiting mitochondrial respiration
EA201691383A1 (ru) Рекомбинантные микроорганизмы и способы их применения
WO2012090554A8 (ja) 微生物の新規な培養方法、新規な元素構成を有する微生物細胞を製造する方法、及び製造された微生物
MX2023004254A (es) La ingeniería genética aumentó los niveles de suberina al alterar los patrones de expresión génica de una manera específica de tipo celular.
WO2021076817A3 (en) Methods and compositions related to treatment and prevention of cancer by inhibition of dgat1 and dgat2
MY186400A (en) Eukaryotic cell with increased production of fermentation product
MX2023012903A (es) Metodo para producir spesolimab.
MX2024002049A (es) Terapia de modulacion personalizada para cancer.
MX2024015744A (es) Proteina de exportacion de l-histidina y metodo de produccion de l-histidina utilizando la misma